IP Library › Granted Patent US 8,168,672
Granted Patent B2
US 8,168,672 · App. 12/698,472 · Granted May 1, 2012

Thioamide derivatives as progesterone receptor modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,168,672
App. No.
12/698,472
Granted
May 1, 2012
Kind
B2
Abstract

Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies.

Claims (48)

1. A method for hormone replacement therapy, treating hormone-dependent neoplastic disease, or synchronizing estrus, said method comprising administering to a mammal in need thereof a compound of formula I of the following structure:

wherein:

R 1 and R 2 are, independently, H, C 1 to C 6 alkyl, or substituted C 1 to C 6 alkyl;

or R 1 and R 2 are fused to form a ring comprising —CH 2 (CH 2 ) n CH 2 —, —CH 2 CH 2 C(CH 3 ) 2 CH 2 CH 2 —, —O(CH 2 ) p CH 2 —, —O(CH 2 ) q O—, —CH 2 CH 2 OCH 2 CH 2 —, or —CH 2 CH 2 NR 6 CH 2 CH 2 —;

n is 1 to 5;

p is 1 to 4;

q is 1 to 4;

R 3 is H, OH, NH 2 , CN, halogen, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 2 to C 6 alkynyl, substituted C 2 to C 6 alkynyl, or COR A ;

R A is H, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl;

R 4 is H, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl;

R 5 is C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, or COR A ;

R 6 is H or C 1 to C 6 alkyl;

X is O or S;

Q is O or S;

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , further comprising administering an estrogen, progestin, estrone, androgen, estrogen receptor agonist, or selective estrogen receptor modulator.

3. A method for contraception, hormone replacement therapy, treating hormone-dependent neoplastic disease, or synchronizing estrus, said method comprising administering to a mammal in need thereof a compound of formula I of the following structure:

wherein:

R 1 and R 2 are, independently, H, C 1 to C 6 alkyl, or substituted C 1 to C 6 alkyl;

or R 1 and R 2 are fused to form a ring comprising —CH 2 (CH 2 ) n CH 2 —, —CH 2 CH 2 C(CH 3 ) 2 CH 2 CH 2 —, —O(CH 2 ) p CH 2 —, —O(CH 2 ) p —, —CH 2 CH 2 OCH 2 CH 2 —, or —CH 2 CH 2 NR 6 CH 2 CH 2 —;

n is 1 to 5;

p is 1 to 4;

q is 1 to 4;

R 3 is H, OH, NH 2 , CN, halogen, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 2 to C 6 alkynyl, substituted C 2 to C 6 alkynyl, or COR A ;

R A is H, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl;

R 4 is H, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl;

R 5 is C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, or COR A ;

R 6 is H or C 1 to C 6 alkyl;

X is absent;

Q is O or S;

or a pharmaceutically acceptable salt thereof.

4. The method according to claim 3 , further comprising administering an estrogen, progestin, estrone, androgen, estrogen receptor agonist, or selective estrogen receptor modulator.

5. A method for contraception, hormone replacement therapy, treating hormone-dependent neoplastic disease, or synchronizing estrus, said method comprising administering to a mammal in need thereof a compound of formula I of the following structure:

wherein:

R 1 and R 2 are, independently, H, C 1 to C 6 alkyl, or substituted C 1 to C 6 alkyl;

or R 1 and R 2 are fused to form a ring comprising —CH 2 (CH 2 ) n CH 2 —, —CH 2 CH 2 C(CH 3 ) 2 CH 2 CH 2 —, —O(CH 2 ) p CH 2 —, —O(CH 2 ) q O—, —CH 2 CH 2 OCH 2 CH 2 —, or —CH 2 CH 2 NR 6 CH 2 CH 2 —;

n is 1 to 5;

p is 1 to 4;

q is 1 to 4;

R 3 is H, OH, NH 2 , CN, halogen, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 2 to C 6 alkynyl, substituted C 2 to C 6 alkynyl, or COR A ;

R A is H, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl;

R 4 is H, C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl;

R 5 is C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, or COR A ;

R 6 is H or C 1 to C 6 alkyl;

X is O, S or absent;

Q is O or S;

or a pharmaceutically acceptable salt thereof.

6. The method according to claim 5 , further comprising administering an estrogen, progestin, estrone, androgen, estrogen receptor agonist, or selective estrogen receptor modulator.